OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
+4.61%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.28%
AUM
$418M
AUM Growth
+$418M
(+25%)
Cap. Flow
+$102M
Cap. Flow
% of AUM
24.46%
Top 10 Holdings %
Top 10 Hldgs %
66.46%
Holding
52
New
11
Increased
13
Reduced
15
Closed
5
Top Buys
| 1 |
SLRN
ACELYRIN
SLRN
|
$86.9M |
| 2 |
Geron
GERN
|
$7.54M |
| 3 |
CBAY
Cymabay Therapeutics
CBAY
|
$6.21M |
| 4 |
Acadia Pharmaceuticals
ACAD
|
$5.2M |
| 5 |
Intellia Therapeutics
NTLA
|
$4.89M |
Top Sells
| 1 |
Arcutis Biotherapeutics
ARQT
|
$5.52M |
| 2 |
TELA Bio
TELA
|
$4.99M |
| 3 |
Phathom Pharmaceuticals
PHAT
|
$3.54M |
| 4 |
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
|
$3.03M |
| 5 |
Cytokinetics
CYTK
|
$2.53M |
Sector Composition
| 1 | Healthcare | 98.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Mineralys Therapeutics
MLYS
$1.94B
| – | – |
-115,000
| Closed | -$1.8M |
|
|
52
Arcutis Biotherapeutics
ARQT
$1.91B
| – | – |
-502,000
| Closed | -$5.52M |
|